Loading stock data…
$0.90
Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease.
Calidi Biotherapeutics, Inc. in the Healthcare sector is trading at $0.90 with a market capitalization of $3M. The stock is currently near its 52-week low of $0.87, remaining 83.6% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 12 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$4.15M↑ | -$4.19M↑ | -$4.47M↑ | -$5.05M↑ | -$5.66M |
| Net Income | -$4.16M↓ | -$4.11M↓ | -$4.06M↑ | -$5.15M↑ | -$5.71M |
Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high gr...